NATCO Pharma Limited invests around US$ 2 million in Cellogen Therapeutics, ET HealthWorld


New Delhi: Cellogen Therapeutics Private Limited, a Delhi-based biotech startup promoted has raised around US$ 2 million from NATCO Pharma Limited. Cellogen is primarily involved in two R&D programs involving cell and gene therapy solutions.

Cellogen Therapeutics has developed bi-specific CARs and also added another co-stimulatory domain to increase the efficacy and persistence of the CAR in the human body as compared to currently available CAR constructs that are mono-specific with one co-stimulatory domain. Both these innovations are aimed at reducing the risk of relapse post CAR T cell therapy which remains a major challenge with existing CAR constructs. Currently available products in the market cost around US$ 500,000 – 700,000 which Cellogen aims to bring down to US$ 60,000 – 70,000.

“Cellogen has been working on its next-generation CAR T programme for around 2.5 years and has been able to zero on one particular CAR construct amongst around 40 such constructs. After successful pre-clinical data using the selected CAR, Cellogen intends to start a phase 1 clinical trial in the first half of 2024. Just like the CAR T cell therapy, Cellogen Therapeutics also intends to bring gene therapy solutions at affordable cost to our patients in need,” said Dr Gaurav Kharya, Founder and Director of Cellogen Therapeutics.

Rajeev Nannapaneni, Director and CEO, NATCO Pharma Limited said, “Cellogen’s area of research work involving innovative and cost-effective cell and gene therapies for addressing various oncological, hematological, and metabolic diseases is in line with our core value of providing advanced healthcare with affordability and is the basis of our investment thesis. We are excited about these therapies and pleased to partner with Cellogen Therapeutics.”

  • Published On Jan 18, 2024 at 04:31 PM IST

Join the community of 2M+ industry professionals

Subscribe to our newsletter to get latest insights & analysis.

Download ETHealthworld App

  • Get Realtime updates
  • Save your favourite articles

Scan to download App


Leave a Reply

Your email address will not be published. Required fields are marked *